Do GLP-1 Drugs Pose a Risk to Lung Transplant Recipients?
People taking GLP-1 receptor agonists appeared to be at elevated risk of rejection episodes after lung transplantation, a small, single-center cohort study suggested. In a retrospective review of 301 consecutive lung transplants, the 34 lung recipients taking a GLP-1 drug for diabetes or obesity early in their post-transplant course had 15.19-fold (95% CI 2.08-23.55, P<0.05) […]
Study Assuages Fears of Pancreatic Cancer Risk With GLP-1 Receptor Agonists
Several years after initiating treatment, GLP-1 receptor agonist users didn’t have a pancreatic cancer safety signal, a historical cohort study reported. Compared with basal insulin users, those on a GLP-1 receptor agonist didn’t have a significantly different risk for developing pancreatic cancer in the 5 to 7 years that followed (HR 0.50, 95% CI 0.15-1.71), […]
Can a GLP-1 Agonist Improve Parkinson’s Symptoms?
An investigational brain-penetrant, pegylated analogue of the glucagon-like peptide-1 (GLP-1) receptor agonist exenatide (Byetta, Bydureon) known as NLY01 did not lead to improvement in Parkinson’s disease symptoms compared with placebo, a phase II trial showed. Neither 2.5 mg or 5.0 mg of weekly NLY01 injections showed any difference from placebo in the sum of Movement […]
Virtual Obesity Treatment Program Led to Substantial Weight Loss in Real-World Study
DALLAS — A real-world virtual obesity treatment program that involved use of GLP-1 receptor agonists with intensive lifestyle interventions led to robust and sustained weight loss, according to an analysis of a cohort study. At 12 months, there was an average weight loss of 16.2% of body weight, with results sustained up to 24 months, […]
Low-Dose Semaglutide Can Ease Insulin Need in Early T1D, Small Series Shows
When used very early on in type 1 diabetes, a GLP-1 receptor agonist may help reduce the need for insulin, a small case series suggested. Ten adults with a new type 1 diabetes diagnosis initially received a 0.125-mg dose of weekly semaglutide (Ozempic), which was adjusted up to a maximum of 0.5 mg per week […]
Near 15% Weight Loss With Novel Oral GLP-1 RA in Phase II Obesity Trial
SAN DIEGO — Orforglipron, an investigational nonpeptide GLP-1 receptor agonist, helped people with obesity lose a significant amount of weight in a phase II trial. Tested at four once-daily doses — 12, 24, 36, or 45 mg — patients on orforglipron lost between 8.6% to 12.6% of body weight compared with a 2% change seen […]
‘Modest’ Erectile Dysfunction Benefit With GLP-1 Agonist
GLP-1 receptor agonist treatment in men with type 2 diabetes may thwart some new cases of erectile dysfunction, an exploratory analysis of a randomized trial suggested. The findings, from the Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial, showed that slightly fewer men developed erectile dysfunction while on long-term treatment with once-weekly […]